AR051802A1 - Heterociclos antagonistas de mchr1 - Google Patents

Heterociclos antagonistas de mchr1

Info

Publication number
AR051802A1
AR051802A1 ARP050105335A ARP050105335A AR051802A1 AR 051802 A1 AR051802 A1 AR 051802A1 AR P050105335 A ARP050105335 A AR P050105335A AR P050105335 A ARP050105335 A AR P050105335A AR 051802 A1 AR051802 A1 AR 051802A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl group
fluorine
group
benzofurane
Prior art date
Application number
ARP050105335A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR051802(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0403119A external-priority patent/SE0403119D0/sv
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR051802A1 publication Critical patent/AR051802A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Los compuestos de formula (1), procesos para preparar tales compuestos, su utilizacion en el tratamiento de la obesidad, trastornos siquiátricos, trastornos cognitivos, trastornos de la memoria, esquizofrenia, epilepsia y afecciones relacionadas, y trastornos neurologicos tales como demencia, esclerosis multiple, mal de Parkinson, corea de Huntington y mal de Alzheimer y trastornos relacionados con el dolor y a composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de formula (1), A representa N, un grupo alquilo C1-4, un grupo alquenilo C2-4, cicloalquilo C3-8, adamantilo, azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, 1,3-oxazidinilo, tetrahidro-piridinilo, o espiro[inden-1,4'- piperidinilo]; donde dicho grupo alquilo C1-4 o grupo alquenilo C2-4 está opcionalmente sustituido con uno o más fluor; X representa un enlace o NR3; donde A y X ambos no presentan nitrogeno; donde cuando A es azetidinilo, 1,3-oxazidinilo, pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, tetrahidropiridinilo, o espiro[1,4'-piperidinilo]; el átomo de nitrogeno en A está directamente unido a C(O); R1 y R2 representan independientemente H, alquilo C1-6, un grupo alquenilo C2-6, cicloalquilo C3-10, CONRaRb en el cual Ra y Rb representan independientemente H, un grupo alquilo C1-4 o Ra y Rb, junto con el nitrogeno al cual están unidos, forman un anillo heterocíclico de 4 a 8 miembros; fenilo o naftilo; o un grupo heterocíclico seleccionado entre pirrolilo, imidazolilo, furilo, tienilo, tiazolilo, isotiazolilo, tiadiazolilo, pirazolilo, oxazolilo, isoxazolilo, piridilo, pirazinilo, pirimidinilo, piridazinilo, quinolinilo, isoquinolilo, quinazolilo, indolilo, benzofuranilo, benzo[b]tienilo, benzimidazolilo, benzotiazolilo, 1,4-benzodioxinilo, 1,3-benzodioxolilo, piperidinilo, morfolinilo, 1,4-oxazepanilo, o 4,4-dioxotiomorfolinilo; donde R1 o R2 está opcionalmente sustituido con uno o más de los siguientes: ciano; halo; hidroxi; oxo; un grupo alquilo C1-4 opcionalmente sustituido con uno o más fluor; un grupo alcoxi C1-4 opcionalmente sustituido con uno o más fluor; un grupo NCORaRb o CONRaRb en el cual Ra y Rb representan independientemente un grupo alquilo C1-3; un grupo SO2alquiloC1-4, opcionalmente sustituido con uno o más fluor, un grupo arilo o heteroarilo seleccionado entre tiadiazolilo, pirazolilo, fenilo, fenoxi, 2-piridilo o 3-piridilo donde dicho grupo arilo o heteroarilo puede estar opcionalmente adicionalmente sustituido con uno o más de los siguientes; ciano; halo; hidroxi; un grupo alquilo C1-4 opcionalmente sustituido con uno o más fluor; un grupo alcoxi C1-4 opcionalmente sustituido con uno o más fluor; un grupo NCORaRb o CONRaRb en el que Ra y Rb representan independientemente un grupo alquilo C1-3; un grupo SO2alquiloC1-4, opcionalmente sustituido con uno o más fluor; R1 y/o R2 está unido opcionalmente a A por medio de oxígeno o por medio de un grupo alquilo C1-4, donde uno de los átomos de carbono en dicho grupo alquilo C1-4 opcionalmente se reemplaza con un átomo de oxígeno; Y representa NR3, C(R5R6) o un enlace; donde al menos uno de A, X o Y es N, NR3 o un anillo heterocíclico que contiene nitrogeno; R3, R5 y R6 representan independientemente H o un grupo alquilo C1-4, D representa (CH2)n, donde n es 0 o 1 y E representa (CH2)m, donde m es 0 o 1; R4 representa H o, cuando m y n ambos son 1, R4 representa H o F; Z representa 2,5-tienilo, 2,5-furilo, o pirrolilo, opcionalmente sustituido con uno o más de los siguientes: ciano, halo, un grupo alquilo C1-4 opcionalmente sustituido con uno o más fluor, un grupo alcoxi C1-4 opcionalmente sustituido con uno o más fluor; W representa fenilo, 2-piridilo o 3-piridilo cada uno de los cuales está opcionalmente sustituido con uno o más de los siguientes: ciano, halo, un grupo alquilo C1-4 opcionalmente sustituido con uno o más fluor, un grupo alcoxi C1-4 opcionalmente sustituido con uno o más fluor; un grupo trifluormetilsulfonilo o un grupo 2,2'-difluor-oxolanilo (fusionado con dos átomos de carbono aromáticos adyacentes en W); así como también sus tautomeros, isomeros opticos y sus racematos así como también sus sales farmacéuticamente aceptables; con la condicion de que cuando Y representa NR3 entonces A-X no representa OCH2, CH2CH2 o CH=CH, donde cada átomo de carbono puede estar opcionalmente sustituido con 1 o 2 grupos metilo y/o 1 o 2 fluor.
ARP050105335A 2004-12-21 2005-12-19 Heterociclos antagonistas de mchr1 AR051802A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0403119A SE0403119D0 (sv) 2004-12-21 2004-12-21 Therapeutic agents
SE0501686 2005-07-15

Publications (1)

Publication Number Publication Date
AR051802A1 true AR051802A1 (es) 2007-02-07

Family

ID=36602060

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105335A AR051802A1 (es) 2004-12-21 2005-12-19 Heterociclos antagonistas de mchr1

Country Status (6)

Country Link
US (1) US20080306055A1 (es)
EP (1) EP1831194A4 (es)
JP (1) JP2008524325A (es)
AR (1) AR051802A1 (es)
TW (1) TW200635589A (es)
WO (1) WO2006068594A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308562B1 (en) 2003-12-25 2015-02-25 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
US8809538B2 (en) * 2009-01-12 2014-08-19 Array Biopharma Inc. Piperidine-containing compounds and use thereof
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
AU2011275547B2 (en) 2010-07-06 2015-10-29 Astrazeneca Ab Therapeutic agents 976
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
JP2014517074A (ja) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用
MX2013015274A (es) 2011-06-24 2014-03-31 Amgen Inc Anatagonista trpm8 y su uso en tratamientos.
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2015057659A1 (en) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
AU2014334551B2 (en) 2013-10-14 2018-05-10 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
TW201627299A (zh) * 2014-10-29 2016-08-01 美國禮來大藥廠 用於抑制微粒體前列腺素ｅ合成酶１之新穎羧酸化合物
BR112017015291B1 (pt) 2015-01-16 2022-10-11 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Método para preparar um estabilizador de nitrocelulose derivado de ureia aromática
PL3390355T3 (pl) 2016-03-22 2023-05-02 Helsinn Healthcare S.A. Benzenosulfonylo-asymetryczne związki mocznikowe i ich zastosowania medyczne

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US6727264B1 (en) * 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
EP1432693A2 (en) * 2001-10-01 2004-06-30 Taisho Pharmaceutical Co. Ltd. Mch receptor antagonists
WO2003031410A1 (en) * 2001-10-09 2003-04-17 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
MXPA04012440A (es) * 2002-06-12 2005-04-28 Abbott Lab Antagonistas de receptor de hormona concentradora de melanina.
US20060178403A1 (en) * 2003-03-07 2006-08-10 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
TW201018661A (en) * 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US20050197350A1 (en) * 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof

Also Published As

Publication number Publication date
JP2008524325A (ja) 2008-07-10
EP1831194A4 (en) 2009-12-02
WO2006068594A1 (en) 2006-06-29
TW200635589A (en) 2006-10-16
EP1831194A1 (en) 2007-09-12
US20080306055A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
AR051802A1 (es) Heterociclos antagonistas de mchr1
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
AR040476A1 (es) N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina)
JP2005527593A5 (es)
RU2008111991A (ru) Органические соединения
PE20071009A1 (es) Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3
AR040351A1 (es) Derivados de quinuclidina-amida, composicion farmaceutica, procedimiento de preparacion del compuesto y su uso para fabricar medicamentos
EP1810972B1 (en) Nitrogenous heterocyclic compound and pharmaceutical use thereof
AR048319A1 (es) Derivados de n-piperidina como moduladores de ccr3
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR036659A1 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
NO306497B1 (no) Anvendelse av piperidinderivater til fremstilling av medikamenter til behandling av psykiske og nevrologiske lidelser
CA2570197A1 (en) Nk1 antagonists
DE602006017543D1 (de) Neue verbindungen
CO5700720A2 (es) Derivados de n-(quinolin-5l) alquilamida-sustituida; n-alquilquinolin-5-carboxamida-sustituida; n-alquilisoquinolin-5-carboxamida-sustituida; n-(isoquinolin-5-yl) alquilamida-sustituida y procesos para su preparacion
DE69528485T2 (de) Biphenylderivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
NO994452D0 (no) Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse
AR035612A1 (es) 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa
AR050435A1 (es) DERIVADOS DE HIDROXIAMIDA, PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS.
AR064547A1 (es) Derivados de azaspiro como antagonistas del receptor v1a
JPH02218665A (ja) ピペラジン誘導体およびその製造方法
AR074184A1 (es) Compuestos de 7-azaspiro[3.5]nonano-7-carboxamida, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de afecciones mediadas por la inhibicion de faah
AR068888A1 (es) Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp.
ATE202099T1 (de) Quinoxalindion-nmda rezeptorantagonisten

Legal Events

Date Code Title Description
FA Abandonment or withdrawal